© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Back in the early days of MRI, contrast agents borrowed ideas from older fields—those early gadolinium complexes gave radiologists a new way to read scans, yet risk and limitations came along for the ride. Gadobutrol showed up in the 1990s after years of hard work in labs, looking for a safer, clearer option so doctors could rely less on trial and error. Bayer led this charge, pushing for a compound that would keep gadolinium tightly locked, limiting toxicity while boosting signal intensity in scans. Clinical trials kept a close eye on patient safety and imaging accuracy, showing Gadobutrol could withstand scrutiny across different populations, eventually leading major healthcare regulators around the world to grant approvals.
Gadobutrol is known as an extracellular, nonionic, macrocyclic gadolinium-based contrast agent. Labs formulate it as a clear, colorless solution, intended strictly for intravenous use in MRI studies. You’ll usually hear doctors call it Gadavist (in the US) or Gadovist (elsewhere), names that show up on drug cabinets and hospital order forms. The molecule forms a ring structure that keeps the gadolinium atom locked within, making it less likely for gadolinium to escape and cause trouble in the body. Each milliliter of solution holds 1 mmol of Gadobutrol, which sits near the upper end for GBCA concentration, helping produce stronger enhancement for images with low administered volume.
The chemical formula for Gadobutrol is C18H31GdN4O8. This macrocyclic structure crafts a tight "cage" around gadolinium, lowering the risk that free ions will leak into tissues. It dissolves completely and does not settle out of solution, ensuring a consistent dose. Molecular mass clocks in at about 604.7 g/mol; this higher value reflects the big, complex frameworks engineers use to hold reactive gadolinium firmly. Gadobutrol remains stable at room temperature, with a pH typically hovering around 6.6 to 8.0, so it doesn’t irritate vessels or degrade quickly. The solution is viscous compared to water and has a faint metallic taste, but patients rarely notice this thanks to intravenous administration.
Vials of Gadobutrol come in airtight, sterile packaging in strengths of 7.5 ml, 10 ml, 15 ml, and 20 ml. Packages include tamper-evident seals and detailed information on proper handling, shelf life, and special instructions for light sensitivity and storage temperature, typically recommended between 15°C and 30°C. The labeling breaks down composition: each mL delivers 604.71 mg of Gadobutrol, with sodium and calcium stabilizers keeping the solution safe for clinical settings. Regulatory agencies in the US and EU include warnings for children, pregnant or breastfeeding patients, and individuals with kidney impairment, as these groups can be more prone to adverse effects. Multilingual inserts and color-coded caps appear in international shipments, following strict norms for traceability.
Gadobutrol starts with a synthetic ligand known as butrol, sidestepping earlier issues linked with open-chain chelators. Chemists bring gadolinium chloride together with the butrol ligand under precise conditions—gentle heating, carefully controlled pH, and lots of purification steps to weed out contaminants. Water purification runs up to pharmaceutical standards, since even tiny bits of impurity can cause dangerous reactions in patients. Final sterilization happens by filtration and heat, then technicians fill vials under nitrogen to keep out air and light, which would compromise stability. Each batch undergoes rigorous testing—chromatography to ensure the right chemical fingerprint, spectrometry for gadolinium content, and microbial screens to reassure hospital staff who administer the product.
Unlike traditional Gd-DTPA and Gd-DOTA complexes, Gadobutrol benefits from a macrocyclic backbone. The ligand wraps around gadolinium, forming a remarkably stable, inert cage that holds up under acidic and neutral conditions. Hydrolysis rates fall far below those seen with linear chelators, so the gadolinium stays bound during transit through the bloodstream and rapid kidney clearance. Attempts to tweak Gadobutrol—such as adding targeting ligands or agents that slow down clearance—show some promise for specialized use in molecular imaging or theranostics, but these haven’t moved into mainstream clinical use yet. Some groups experiment with polymer-linked Gadobutrol to slow its washout, potentially extending image acquisition time for complex vascular studies.
Gadobutrol appears on regulatory forms under the name 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-(butan-2-ol)amide gadolinium(III) complex, though hardly anyone outside a chemistry lab uses the full name. Hospitals know it as Gadavist, Gadovist, or generic Gadobutrol. These branded forms draw on the same central formula and go through the same manufacturing standards, so switching from one to another produces consistent results for doctors and patients. Database entries and global shipping papers rely on these recognized designations to avoid confusion with other gadolinium-based products.
Gadobutrol carries a strong safety profile compared to some older contrast agents, but risk never fully disappears. The most common problems in the general population involve mild reactions like headaches or a warm flush; severe allergic responses remain very rare. The real challenge comes for patients with kidney problems—these individuals bear the brunt of nephrogenic systemic fibrosis, a potentially lethal complication that led the FDA and EMA to enforce stricter screening and risk communication. Nurses and radiologists keep emergency epinephrine, oxygen, and crash carts ready just in case, and protocols call for thorough pre-procedural questionnaires about kidney health and history of contrast reactions. Routine monitoring, including renal function screens and post-injection observations, form the backbone of safety at major imaging centers.
Hospitals reach for Gadobutrol during everything from routine brain tumor follow-ups to subtle vascular malformations and even pediatric body imaging. High relaxivity, meaning strong signal with low volume, means doctors can catch details like tiny white-matter lesions, narrowing of blood vessels, or abnormal tissue without needing hefty, repeated doses. Emergency rooms rely on its rapid renal clearance to quickly assess trauma or acute stroke; in some cases, lower osmolality proves gentler on patients with fragile veins. Cancer centers use Gadobutrol as a tool for early tumor detection and watchful waiting, since it reliably highlights tissues with abnormal blood flow or breakdown of the blood-brain barrier.
Research teams continue to push Gadobutrol toward new clinical territory, taking on problems like early Alzheimer’s, advanced cardiac fibrosis, and rare genetic diseases with a vascular component. Recent clinical trials look at ways to pair it with functional MRI or PET tracers for combined imaging, blending soft tissue detail with molecular signatures. Oncology groups run head-to-head studies pitting Gadobutrol against other GBCAs for tumor delineation, often finding sharper boundaries in especially tough cases. The race for precision medicine keeps chemists and technologists busy, hoping they can stick extra functional groups onto Gadobutrol and target it to specific proteins or cell types, opening doors to personalized disease mapping.
No one wants contrast agents hanging around the body for longer than needed. Researchers focus on two big risks—systemic toxicity from gadolinium leakage, and organ-specific injuries, especially with repeated administration. Animal studies and human trials show that Gadobutrol sticks tightly to its cage structure, resulting in rapid, near-complete renal excretion with very limited trace deposition in tissues. Surveillance systems check for late complications and monitor at-risk groups, especially in pediatric and pregnant populations. Regional differences in genetic makeup have prompted special studies in Asia and the Middle East, looking for population-specific side effects, but so far, rates remain comfortably low. Ongoing clinical trial registries keep track of rare but serious complications, responding rapidly if any hint of unexpected toxicity creeps into the data.
Gadobutrol holds a unique spot at the intersection of safety, clarity, and flexibility. Future medical practice asks for imaging agents that do more than simply light up a scan—doctors and researchers imagine designer molecules able to lock onto fingerprints of diseases even before symptoms start. AI and machine learning may use detail-rich Gadobutrol-enhanced scans to train neural networks for early cancer or vascular anomaly detection. Other research teams pursue slow-release and nanoparticle-bound forms to stretch out imaging windows or track therapies over days rather than minutes. As global access to MRI widens, Gadobutrol serves as the steady workhorse, but the next wave—combining molecular tags for theranostic imaging or targeted therapy—could transform it from passive tool to active disease-fighter.
Gadobutrol gets talked about as a "contrast agent for MRI scans," which sounds pretty dry unless you've spent time in a chilly imaging room, hearing the whir of a machine while someone tells you to hold your breath. This clear liquid, injected right before the scan, helps doctors see what's really going on inside the body—especially in the brain, spine, blood vessels, and even some pesky tumors hiding in plain sight.
I remember hearing a neurologist describe how black-and-white MRI pictures can sometimes miss small lesions in a patient’s brain. Add Gadobutrol to the recipe and those tiny, previously hidden details can pop into view. This becomes crucial for someone worried about multiple sclerosis or a suspected brain tumor. Missing a detail could mean months without the right treatment, risking damage that can't get undone.
It also plays a big role in heart care. Cardiologists use it to map out damaged heart tissue after a heart attack, measure blood flow, and even guide delicate procedures. For people with stubborn high blood pressure, Gadobutrol-enhanced scans sometimes help spot narrowings in the arteries that need fixing.
Not all contrast agents are built the same. I talked to a radiologist who explained that Gadobutrol packs more gadolinium into each milliliter than most other agents. This higher concentration means doctors can use a smaller dose to achieve sharper images, which often leads to faster exams. Faster scans help kids, older folks, and people dealing with anxiety get through the process with less stress.
Its safety track record means a lot too. Gadobutrol is less likely to leak out into tissue, especially compared to older agents, and it usually leaves the body quickly through urine. People with healthy kidneys barely notice it’s there. In people with kidney problems though, any MRI contrast deserves extra thought. Reports of a rare skin disorder, nephrogenic systemic fibrosis, have pushed hospitals and providers to review kidney numbers before using these agents. Most guidelines now say Gadobutrol can be used in certain kidney patients, but only after weighing the risks.
There’s always the question of cost. Gadobutrol carries a higher price tag than some generic contrast dyes. Health systems need to balance quality images with budgets that only stretch so far. In some communities, especially rural ones, smaller clinics don't always offer advanced imaging with this contrast. Patients sometimes travel hours to get the test, which can mean lost work, gas money, or leaving kids with a neighbor.
Education stands front and center. More doctors are learning when to choose Gadobutrol for better results, and patients who understand why it’s ordered tend to follow up with appointments. Hospitals and manufacturers could work together to help people with limited resources get access, whether through partnerships or patient support programs.
Every time that needle goes in and scans light up a knot of blood vessels or a growing tumor, it’s a reminder that seeing inside the body isn’t just science—it can change the whole direction of someone’s care. Gadobutrol makes those images clearer, and in medicine, that clarity changes lives.
Gadobutrol adds sharpness and clarity to magnetic resonance imaging (MRI) scans. This contrast agent helps radiologists spot injuries and diseases that regular MRI might leave hidden in the shadows. People dealing with lingering headaches or suspected tumors often confront the puzzling ambiguity of blurry scans. Gadobutrol aims to clear that up. In most cases, patients get this compound as an injection right before their scan, which lets doctors see organs and blood vessels much better.
Nurses introduce Gadobutrol straight into a vein, often using a small needle in the arm or hand. Hospitals typically base the amount on the person’s weight. It doesn’t involve long setups—just a brief explanation, a quick disinfecting of the skin, and the swift pinch of a needle. Most imaging centers use either manual injections or connect the syringe to a power injector, especially if timing matters. Power injectors make sure the solution flows into the bloodstream at a steady rate. Medical teams watch for comfort, making adjustments if anyone shows signs of discomfort.
The benefits of precise delivery reach well beyond sharp images. The clearer the contrast, the more confidently doctors can spot problems, track progress, or plan surgeries. Even faint differences between types of tissue stand out more under a scan. Early detection changes outcomes for stroke and cancer patients, giving them real chances at recovery or successful treatment. My own family has leaned on these enhanced images after a scary health episode; knowing that nothing significant was missed because of murky imaging brings lasting reassurance.
Some people worry about contrast agents thanks to past stories of allergic reactions. The data paints a reassuring picture for Gadobutrol: side effects are pretty rare and mostly mild. The most common complaint might be a warm feeling or slight discomfort where the needle goes in—nothing that lingers. Hospitals keep a close eye on anyone with kidney troubles. Not everyone realizes that kidney function directly impacts how fast the body clears the agent. Before injection, staff often check recent lab results to be safe, especially in older or chronically ill patients.
Genuine comfort starts with clear communication from staff. Too often, anxiety springs from the unknown. Staff who take a couple of minutes to explain what’s happening and encourage questions tend to see calmer, more cooperative patients. Manufacturers continue to fine-tune formulas for safety and less discomfort. Smaller needles and faster procedures mean less stress and lower risk for bruising or pain. Hospitals can also adopt software that reduces the overall amount of contrast needed. Less exposure, fewer risks—and high-quality results.
Experience and research combine to show that careful administration of Gadobutrol supports more accurate, earlier diagnoses. Radiology teams equipped with both technical know-how and human empathy can ease a daunting process and deliver answers that transform lives. From a patient’s viewpoint, every improvement in safety and comfort counts. Assurance comes not just from clearer scans, but from trust in the hands guiding the process.
Gadobutrol plays a critical part in magnetic resonance imaging (MRI). With doctors relying on clear images to spot health issues like tumors or blood vessel problems, this contrast agent has become a tool many clinics use. It makes certain tissues stand out in scans, which can help catch things earlier and guide lifesaving decisions.
Plenty of folks walking into the MRI suite feel nervous. Seeing that syringe filled with contrast, people wonder what might happen once it enters their system. In my own experience as a patient, nurses usually explain that most people handle Gadobutrol just fine, but some do go through mild discomfort. Nausea tops the list, often followed by headaches. Both symptoms show up soon after injection, and they tend to fade quickly—usually before a person heads home.
Other effects can visit, too. People sometimes feel a prickling or burning near the injection site. A sense of warmth, or what some describe as “flushing,” can spread from head to toe. Even a metallic taste in the mouth pops up for some. These reactions rarely last longer than a few minutes.
For a tiny number, the side effects demand more attention. Signs such as itching, hives, or trouble breathing hint at an allergic reaction. I remember hearing stories from radiology professionals about those rare days when teams must act fast to treat allergic symptoms. The U.S. Food and Drug Administration reports that life-threatening reactions happen in less than 1 in 10,000 cases. Clinics prepare for these moments with quick access to emergency medications and by screening patients for previous allergies before the scan.
Most people clear Gadobutrol through their kidneys with no issue. Discussions about risk ramp up for patients who have impaired kidney function. The agent can stick around in the body longer, and this delayed clearance may lead to a condition called nephrogenic systemic fibrosis (NSF). NSF stiffens skin and connective tissues, and it’s as serious as it sounds. Thankfully, guideline changes now call for checking kidney health ahead of time. In my job at a clinic, we always checked creatinine levels for certain patients before setting up their MRI.
Some people might feel dizzy, start sweating, or notice a bit of vomiting. These events show up less often but can add to anxiety, especially in busy hospitals. Staff now keep close tabs on anyone feeling unwell and stay ready with fluids, medications, or a call to the doctor.
Doctors and radiology teams share info about possible side effects up front. Everyone gets a shot at asking questions and flagging past reactions. Good communication lowers stress and keeps patients safe. Sharing personal experiences—whether you felt fine or had side effects—helps care teams improve their approach.
Honest conversations about allergies and kidney health lay the groundwork for safer scans. Drinking water after the procedure speeds up elimination for those with healthy kidneys. Medical teams watch closely for trouble during and after the scan, ready to act at the first signs of a reaction.
By understanding both the benefits and the burdens of Gadobutrol, patients and staff work together toward better outcomes—proving that knowledge and teamwork can make all the difference in healthcare.
MRI scans often depend on contrast agents to create sharper images. Gadobutrol, one of these agents, promises high-definition snapshots of what’s going on inside the body. But not every medicine fits every patient, especially those with kidney issues. Many people with kidney disease know the drill—complicated rules before scans, possible delays, and honest concern from their medical team. That worry goes double once the word "gadolinium" enters the conversation.
Gadolinium lives at the center of a big debate because of one word: nephrogenic systemic fibrosis (NSF). This rare but serious illness can show up in people with poor kidney function after receiving some gadolinium-based contrast agents. NSF causes thick, hard skin and can even limit a person’s movements. Years ago, a friend of mine, already on dialysis, had to get a scan. The medical team paused, double-checked his kidney status, and debated which contrast to use, if any. A bad call here isn't just an inconvenience—it can mean pain long after the scan finishes.
I dug into medical research and the FDA’s own records. Gadobutrol falls into a group called macrocyclic gadolinium agents. These come with lower NSF risk than older, linear agents, because their chemical structure holds the gadolinium more tightly and limits its release in the body. The American College of Radiology agrees—reports show zero confirmed NSF cases from gadobutrol in patients with mild or moderate kidney trouble. Even for folks on dialysis or with advanced kidney failure, only a handful of case reports raised concern, but no solid pattern appeared.
For anyone facing a scan, trust builds on straight talk. Some medical staff rush through explanations, but most patients want simple truths. No, all gadolinium agents aren’t alike. Many older agents did spark NSF cases. Gadobutrol seems much safer—study after study backs that up. Still, you can’t just throw caution to the wind. Doctors today often weigh the benefits and risks, sometimes opting out of contrast studies in the sickest kidney patients unless the scan absolutely matters. They may also schedule dialysis sessions close to the scan to help clear out any lingering contrast.
Stronger screening, patient education, and tighter record keeping all lower the chances of problems. Hospitals now track every use of gadolinium contrast, flag people at risk, and rely on macrocyclic agents nearly exclusively. Regulatory agencies keep reviewing new safety data and updating guidelines. My own experience working with diabetic and kidney patients showed real impact from these policy shifts: less anxiety among patients, more trust, and fewer avoidable complications.
If you have kidney problems and need an MRI with contrast, ask these questions: What type of contrast will you use? Why is it necessary? How will you protect my kidneys? In my years talking with patients, those who take an active role in these decisions feel more confident and tend to get better care. Recent science may give some comfort—gadobutrol stands out for safety in the right hands. Still, that reassurance matters most when paired with honest conversations and a plan that really fits the person, not just their test results.
Gadobutrol shows up in hospitals as a contrast agent for MRI scans. It’s one of those substances that sharpen the detail in a brain scan or help doctors find out what’s going on in the kidneys or heart. Plenty of adults have received gadobutrol safely, but parents and doctors still pause before putting it in a child’s IV. Kids aren’t little adults, and medical decisions often need to be weighed with more care when children are the ones facing the needle.
Looking at real-world results, studies that tracked children who received gadobutrol found serious side effects to be rare. The FDA already lists approved pediatric use, starting at birth, with over a decade of data from Europe backing that up. When researchers look for problems, they tend to find mild symptoms—nausea, headache, or itching. Severe allergic reactions happen very rarely, and the risk does not stand out any more than with similar MRI contrast agents.
I remember sitting across from parents as a pediatric resident, trying to answer questions about what’s actually known. The hardest questions aren’t about statistics—they’re about what could happen to their kid. Families want straight facts, not fine print. So it helps to remember that real-life use and formal studies both suggest the drug plays it safe in children. Long-term worries, like the chance of gadolinium building up in the brain, haven’t shown evidence of causing harm in the years since these agents started getting used in kids routinely.
Deciding to use gadobutrol in a child isn’t a snap decision. Doctors look at the alternatives first. Sometimes the extra detail from a contrast MRI reveals a tumor, infection, or injury that plain MRI would miss. Catching that early could mean faster treatment and better recovery. Risk isn’t zero, but skipping the test could mean a dangerous delay or the wrong treatment. That tradeoff looks different for every child. For example, if a child has severe kidney disease, the team slows down and weighs every option, because rare but serious complications can happen in cases of kidney failure.
Medical societies and government agencies help keep standards tight. They call for using the lowest dose that will get the job done, checking kidney function first, and talking with the family before going ahead. Parents get to hear the real numbers behind the risks and reasons for using contrast—nothing gets hidden. This helps families stay in control of medical decisions.
Radiology departments also have emergency medication and trained staff ready, just in case a reaction does pop up. It’s not just about sticking to the rules—these details mean families can trust the process isn’t rushed and their child’s safety stays front and center.
Even though studies show gadobutrol’s safety in children, health care can always do better. More research with larger groups and longer follow-up after scans can reassure families and clinicians even further. Making it standard for families to ask questions and get honest answers, not just a pamphlet, can cut anxiety. Keeping records on every child who receives gadobutrol, from babies to teens, means hospitals keep learning from real outcomes, not just trial data.
In the end, using gadobutrol with kids grows from careful science and shared decision-making, not routine. That keeps the focus on each child’s needs, while still grounding every choice in facts and experience.
| Names | |
| Preferred IUPAC name | 10-[(1RS)-1-hydroxy-3-(N-methylglucamido)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid gadolinium(III) |
| Other names |
Gadovist Gadavist |
| Pronunciation | /ɡæd.oʊˈbjuː.trɒl/ |
| Identifiers | |
| CAS Number | 119545-06-1 |
| Beilstein Reference | 7933457 |
| ChEBI | CHEBI:70755 |
| ChEMBL | CHEMBL1201195 |
| ChemSpider | 3672609 |
| DrugBank | DB08833 |
| ECHA InfoCard | GE-700-015-5J5 |
| EC Number | 68179-86-6 |
| Gmelin Reference | 754451 |
| KEGG | D08045 |
| MeSH | D000077337 |
| PubChem CID | 158057 |
| RTECS number | LC6284000 |
| UNII | JW795ZZ38P |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C18H31GdN4O9 |
| Molar mass | 604.7 g/mol |
| Appearance | Clear, colorless to pale yellow solution |
| Odor | Odorless |
| Density | 1.27 g/cm³ |
| Solubility in water | freely soluble |
| log P | -3.1 |
| Vapor pressure | Vapor pressure: negligible |
| Acidity (pKa) | 11.3 |
| Basicity (pKb) | pKb = 2.6 |
| Magnetic susceptibility (χ) | +0.000021 |
| Refractive index (nD) | 1.343 |
| Viscosity | 12 mPa·s |
| Dipole moment | 3.5 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 302.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -3674 kJ/mol |
| Pharmacology | |
| ATC code | V08CA09 |
| Hazards | |
| Main hazards | May cause allergic reactions, including anaphylaxis; nephrogenic systemic fibrosis in patients with severe renal impairment. |
| GHS labelling | GHS07 |
| Pictograms | GHS07, GHS08 |
| Hazard statements | No hazard statements. |
| NFPA 704 (fire diamond) | NFPA 704: 1-0-0 |
| Flash point | > 100°C |
| Lethal dose or concentration | LD50 (intravenous, rat): 23.3 mmol/kg |
| LD50 (median dose) | > 17.4 mmol/kg (rat, intravenous) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 1 mmol/kg body weight intravenous |
| Related compounds | |
| Related compounds |
Gadoteridol Gadodiamide Gadopentetic acid Gadoterate meglumine Gadobenic acid Gadoxetate disodium |
